Justine Michaux

University Hospital of Lausanne — Switzerland

Immunology and Microbiology · Life Sciences

24h-index2.2kcitations72works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(29), vaccines and immunoinformatics approaches(28), CAR-T cell therapy research(23), Monoclonal and Polyclonal Antibodies Research(16), Ferroptosis and cancer prognosis(14)

Publications72 total

Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics
Nature Communications·2025· 5 citedOpen Access
Circulating tumor‐associated and neoantigen‐specific endogenous T cells in children treated for B‐acute lymphoblastic leukemia
HemaSphere·2025Open Access
Phage display enables machine learning discovery of cancer antigen–specific TCRs
Science Advances·2025· 8 citedOpen Access
Deleterious KOs in the HLA Class I Antigen Processing and Presentation Machinery Induce Distinct Changes in the Immunopeptidome
Molecular & Cellular Proteomics·2025· 5 citedOpen Access
Supplementary Figure 8 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 9 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary methods from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Data from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 6 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 5 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 4 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy
Nature Biotechnology·2024· 65 citedOpen Access
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
Cancer Discovery·2024· 7 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Michal Bassani‐Sternberg(50), HuiSong Pak(29), George Coukos(24), Florian Huber(21), David Gfeller(13), Brian J. Stevenson(12), Evarist Planet(12), Didier Trono(12), Julien Racle(12), Alexandre Harari(10), Markus Müller(9), Olga Rosspopoff(9), Joana Carlevaro-Fita(9), Romain Forey(9), Sandra Offner(9), Cyril Pulver(9), Priscilla Turelli(9), Philippe Guillaume(8), Filipe Martins(8), Chloé Chong(7)